In a phase I trial as monotherapy, the best response was SD (26%) in patients with colorectal cancer, pancreatic carcinoma with a K-RAS mutation, head and neck squamous cell carcinoma, and basal cell carcinoma (NCT01014429) [68]. Here, KRAS is linked to exocrine pancreatic carcinoma.